The targeted therapy results are similar to the findings in our previous work in metastatic HER2-positive breast cancer treated with dual HER2-targeted therapies,9 where the simple multiples method was accurate for the short-term outcomes but follow-up was insufficient to quantify the best-case scenario. Here, ERBB2 is linked to breast carcinoma.